Announcement PDF ASX Announcement 16 July 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Q4 FY26 Quarterly Investor Presentation & Webinar Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q4 FY26 Investor Presentation and Investor Webinar with CEO, Dr Luke Reid presenting. Quarterly Investor Webinar Presented by: CEO, Dr Luke Reid Date & Time: 12:00pm (Midday) AEST (Brisbane/Sydney/Melbourne) on Thursday, 16 July 2026 Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via Microba’s Investor Hub at the following link: https://ir.microba.com/webinars/yOO1wy-q4-fy26- quarterly-investor-webinar Webinar Recording: A recording will be made available at the same link following the conclusion of the live webinar. Submit Your Questions We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the ‘Ask a question’ section of Microba’s interactive investor platform by following this link: https://ir.microba.com/webinars/yOO1wy-q4-fy26-quarterly-investor-webinar Stay Informed To receive notifications when Microba releases its Quarterly Reports & Appendix 4C, Investor Presentations, and other key announcements, sign up to the Microba Investor Hub: 1. Visit https://ir.microba.com/welcome 2. Follow the prompts to sign up for an account. 3. Complete your account profile. This announcement has been authorised for release by the Board of Directors For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com Building the platform for personalised, microbiome-based healthcare Q4 FY26 Results Authorised for release by the Board of Directors ASX: MAP 16 JULY 2026 1 Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above. Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended. Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance. Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright. Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation. 2 MICROBA.COM EXPECT BETTER MICROBA.COM EXPECT BETTER MICROBA LIFE SCIENCES LTD © ALL RIGHTS RESERVED Q4 FY26 Financial Highlights Section 1 Strong Q4 Core Testing Growth +54% YoY volume. Annualised run rate of 25,000+ 4 Core Testing includes Microbiome Explorer and MetaPanel across Australia and the United Kingdom 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Test volume (units) Quarterly Core Testing Volume Strong FY26 Core Testing Growth +78% YoY volume. +92% YoY revenue. 5 Core Testing includes Microbiome Explorer and MetaPanel across Australia and the United Kingdom $0.0M $1.0M $2.0M $3.0M $4.0M $5.0M $6.0M $7.0M $8.0M $9.0M 0 5,000 10,000 15,000 20,000 25,000 FY2024 FY2025 FY2026 Revenue ($) Test volume (units) Annual Core Testing Volume & Revenue Total Core Tests (units) Total Revenue ($) Strong FY26 Continuing product growth +53% YoY Continuing revenue. -72% YoY Discontinued revenue. 6 Continuing products includes Microbiome Explorer, MetaPanel, GI Navigator, key partners (Sonic, SYNLAB & Genova), and Invivo Supplements Discontinued products includes Insight, legacy partners (e.g. G42), DFH distributed supplements $0.0M $2.0M $4.0M $6.0M $8.0M $10.0M $12.0M $14.0M $16.0M $18.0M FY2024 FY2025 FY2026 Revenue ($) Continuing Discontinued Annual Continuing & Discontinued Product Revenue MICROBA.COM EXPECT BETTER MICROBA.COM EXPECT BETTER MICROBA LIFE SCIENCES LTD © ALL RIGHTS RESERVED Q4 FY26 Business Highlights Section 2 Key Highlights Sub-Section 2.1 8 9 Growing key enterprise accounts in Australia • In Australia, adoption has now moved beyond innovators into early adopters, increasingly characterised by enterprise-style contracts with healthcare clinics. • Since we commenced targeting these key accounts in November 2025, we have already signed 43 accounts and sold over 5,600 tests, up 87% QoQ. These accounts represent an ordering potential of over 24,000 tests per annum. • There are over 175 key account targets currently in the pipeline in Australia, with an estimated ordering potential of over 80,000 tests per annum. 0 5 10 15 20 25 30 35 40 45 0 1,000 2,000 3,000 4,000 5,000 6,000 Q2 YTD (to Dec-25) Q3 YTD (to Mar-26) Q4 YTD (to Jun-26) # Signed Key Accounts Test volume Australia – Enterprise Key Account Growth Tests Accounts Upcoming New Product Release 10 New Test Release On track to launch GI Navigator, a new category-defining testing product, in September 2026. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. It represents a meaningful leap in the clinical application of complete microbiome and gut testing and is expected to open up our serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for our tests. GI Navigator is live now with a closed-group early access cohort of opinion-leading practitioners across AU and UK, with the first 35 sales achieved: multiple parts of the product are already delivering clinical value and receiving positive feedback, the new product is powered by Microba’s proprietary one-of-a-kind Clinical Logic Engine. Targeting release in Q1 FY27 Diagnostic Results Sub-Section 2.2 11 Strong growth in Core Test sales and clinical adoption in Australia 12 0 5,000 10,000 15,000 20,000 25,000 FY2024 FY2025 FY2026 Core Test Volume 0.0 2.0 4.0 6.0 8.0 10.0 12.0 - 200 400 600 800 1,000 1,200 1,400 1,600 1,800 FY2024 FY2025 FY2026 # Av Orders / clinician # Ordering Clinicians Ordering Clinicians & Orders Per Clinician Ordering clinicians Orders per clinician Strong growth in Core Test Volume • Q4 Microbiome Explorer AU test sales of 5,311, up 54% vs PCP • Q4 Microbiome Explorer AU annualised run- rate of 21,000+ tests sold • Q4 MetaPanel AU test sales of 225, down 15% vs PCP Strong growth in orders per clinician • Ordering clinicians grew 22% YoY, whilst orders per clinician grew by 34% YoY, representing the focus in Australia on signing and maturing key enterprise accounts sales Continued progress in UK market development for Microbiome Explorer Progress in UK market development • Q4 Microbiome Explorer UK test sales of 825, up 92% vs PCP • Q4 Microbiome Explorer UK annualised run- rate of 3,300 tests sold Growing clinician accounts and orders per accounts • Ordering clinicians grew 230% YoY, alongside orders per clinician growing by 37% YoY 13 0 500 1,000 1,500 2,000 2,500 3,000 3,500 FY2024 FY2025 FY2026 Core Test Volume 0.0 1.0 2.0 3.0 4.0 5.0 6.0 - 100 200 300 400 500 600 700 FY2024 FY2025 FY2026 # Av Orders / clinician # Ordering Clinicians Ordering Clinicians & Orders Per Clinician Ordering clinicians Orders per clinician Supplement Results Sub-Section 2.3 14 Supplement growth focused on Invivo branded products • Invivo Supplements revenue of $0.75m in Q4, up 11% QoQ and up 11% vs PCP • Invivo’s leading supplement PHGG’s unit sales more than doubled to 43,000 units in FY26, up 114% v FY25. • The Invivo subscription offering, launched in late 2025, grew 230% over the six months to 30 June 2026, and now has more than 1,000 subscribers. • The Invivo supplement business continues to accelerate its transition to a focus on high margin Invivo branded products. 15 $0.0M $0.2M $0.4M $0.6M $0.8M $1.0M $1.2M $1.4M $1.6M H2FY25 H1FY26 H2FY26 Supplement Revenue Invivo Supplements DFH (Legacy) 0 200 400 600 800 1,000 1,200 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Supplements Subscriber Growth Therapeutic Partnering Sub-Section 2.4 16 Active partnering for pipeline of therapeutic assets backed by big-data, preclinical and clinical validation LBP = Live Biotherapeutic Product • 5+ years of investment to develop a rich pipeline of live biotherapeutic assets and data, leveraging Microba’s world leading databank generated from its testing business • Multiple microbiome therapeutics sector read outs delivered since Nov-25 validating the modality for pharma partners • Microba's Therapeutics division is active in a partnering process with a Boston-based advisor for its field-leading assets • Recent deal precedents ranging between $1.5 – $11B Therapeutic Assets Sector Momentum Multiple positive microbiome therapeutics sector read outs delivered since Nov-25 continue to validate the live biotherapeutic modality across multiple chronic diseases for pharma partners. Microba maintains its competitive advantage in human data-driven discovery from the human microbiome and holds field-leading live biotherapeutic IP assets with deep preclinical and early clinical validation, including MAP- 315, which is near Phase 2 ready. All further internal R&D investment remains paused, as previously guided. Focus & Catalysts Sub-Section 2.5 18 Key areas of focus & catalysts Break-even • Streamlining operations to a structurally lower cost base • Full group break-even on run-rate basis in CY2027 Diagnostics • Australia - continued growth in test sales and clinical adoption • United Kingdom - continued growth in test sales and clinical adoption • New GI Navigator test release Therapeutics • Active in formal partnering process off the back of recent positive sector trial readouts Corporate Snapshot ASX Code MAP Market capitalisation1 $28.71m Shares on issue 700.31m 52-week low / high1 $0.036 / $0.105 Cash Balance (30 Jun 2026) $7.95m Major Shareholders Shareholder Ownership %2 Sonic Healthcare 21.68% Perennial 13.62% Mercer Investments (Australia) 7.59% Thorney Investment Group 7.17% 1 At 15 July 2026 | 2 As per latest substantial shareholder notice lodged to the ASX 19 MICROBA.COM EXPECT BETTER MICROBA LIFE SCIENCES LTD © ALL RIGHTS RESERVED Share Purchase Plan MICROBA.COM EXPECT BETTER Share Purchase Plan (SPP) Details Every new share is offered at $0.05 and includes one free attaching option – on the same terms as the institutional placement. SPP Closing Date –Tuesday 22 July 2026 Key terms Offer price $0.05 per new share Attaching options One free unlisted option per new share (1:1) Option exercise price $0.0625 Option expiry Three years from the date of issue Maximum application $30,000 per eligible shareholder Brokerage None Illustrative application amounts Application amount New shares Free attaching options $2,500 50,000 50,000 $5,000 100,000 100,000 $10,000 200,000 200,000 $30,000 (maximum) 600,000 600,000 Attaching options are unlisted and exercisable at $0.0625 until three years from the date of issue. The SPP New Shares and attaching options are subject to shareholder approval at the General Meeting on 24 July 2026 and are offered under a prospectus. Share and option numbers are illustrative only, based on the $0.05 offer price and rounded. This is a summary only and not financial product advice – refer to the SPP offer booklet and prospectus for full terms. MICROBA.COM EXPECT BETTER How to participate in the SPP Who can participate Shareholders registered in Australia and New Zealand on the record date, Thursday 11 June 2026. How much you can invest Any amount up to a maximum of $30,000, at $0.05 per new share. No brokerage applies. How to apply 1. Read the SPP offer booklet and prospectus sent to eligible shareholders (also available on the Microba website and ASX). 2. Pay via BPAY using the reference in your personalised offer, or apply online. 3. Ensure your application and payment are received before the offer closes. Key dates Event Date Record date Thursday, 11 June 2026 Offer opens Friday, 19 June 2026 Offer closes Wednesday, 22 July 2026 General Meeting (shareholder approval) Friday, 24 July 2026 SPP shares and attaching options issued Wednesday, 29 July 2026 Trading of SPP shares commences Thursday, 30 July 2026 The SPP New Shares and attaching options are subject to shareholder approval at the General Meeting and are offered under a prospectus. Dates are indicative and may change. This is a summary only and not financial product advice – refer to the SPP offer booklet and prospectus for the full terms and conditions. MICROBA.COM EXPECT BETTER Timetable Event Date Record Date for entitlement to participate in SPP Thursday, 11 June 2026 Voluntary Suspension lifted and announcement to ASX of the Placement and SPP Friday, 12 June 2026 Settlement Date of New Shares (Placement) Wednesday, 17 June 2026 Issue of New Shares (Placement) Thursday, 18 June 2026 Lodgement of the Prospectus - SPP (Shares and Attaching Options) and the Attaching Options for the Placement Friday, 19 June 2026 Offers open under the Prospectus Friday, 19 June 2026 Dispatch Notice of Meeting (NoM) Tuesday, 23 June 2026 Offers close under the Prospectus Wednesday, 22 July 2026 Extraordinary General Meeting (EGM) - to approve all Placement Attaching Options and the New Shares and Attaching Options under the SPP Friday, 24 July 2026 Issue of New Shares under the SPP Offer and the issue of all Attaching Options under the Placement and SPP Wednesday, 29 July 2026 Commencement of trading of New Shares issued under the SPP Thursday, 30 July 2026 Any shares to be taken up by Directors under the Placement will be subject to approval at the EGM with the Shares and attaching options issued after the EGM date. Contact Head Office Level 10, 324 Queen Street Brisbane QLD Australia Laboratory Princess Alexandra Hospital Woolloongabba QLD Australia Dr Luke Reid Chief Executive Officer luke.reid@microba.com Pasquale Rombola Chair pasquale.rombola@microba.com 24